菌物学报2026，Vol.45Issue(2)：110-116,7.DOI:10.13346/j.mycosystema.250096
黄曲霉中唑类耐药基因Cyp51突变位点鉴定
Identification of the Cyp51 mutation site of the azole resistance gene in Aspergillus flavus
摘要
Abstract
The molecular characterization and phenotype identification of resistance mutations of azole resistance genes cyp51A,cyp51B and cyp51C of 6 clinical Aspergillus flavus isolates from Xinjiang are carried out.The isolates were identified based on internal transcribed spacer(ITS)and BenA gene sequencing.The Sensititre Yeastone Fungal Drug Sensitivity Kit was used to detect the in vitro antifungal susceptibility of 7 drugs,and the MIC/MEC results were interpreted according to the standards recommended by CLSI M57S.The cyp51A,cyp51B and cyp51C genes of A.flavus strains were amplified and sequenced by PCR,and the sequencing results were compared with the reference strain of A.flavus to identify the resistance mutation phenotype.All 6 clinical isolates were identified as A.flavus.The results of antifungal susceptibility test showed that the isolated A.flavus strains were completely sensitive to echinocandins,itraconazole and posaconazole;of which 1 strain was resistant to amphotericin(8 μg/mL)and 2 strains were resistant to voriconazole(4 μg/mL).Sequencing of the cyp51A,cyp51B,and cyp51C genes of 2 azole-sensitive and 4 azole-resistant strains revealed that both cyp51A and cyp51C in sensitive and resistant strains showed synonymous and non-synonymous point mutations,and no mutation was found in cyp51B.However,the P276T mutation site in cyp51C gene was only found in one resistant isolate.Echinocandins,itraconazole and posaconazole showed better antifungal activity against A.flavus,while voriconazole and amphotericin showed lower antifungal activity against A.flavus.Probably cyp51C gene mutation of A.flavus is associated with azole resistance.关键词
黄曲霉/抗真菌药物敏感性/唑类耐药/cyp51基因Key words
Aspergillus flavus/antifungal susceptibility/azole-resistance/cyp51 gene引用本文复制引用
艾柯代·玉苏甫,祖拜旦木·艾则孜,哈地利亚·哈斯木,王晓东..黄曲霉中唑类耐药基因Cyp51突变位点鉴定[J].菌物学报,2026,45(2):110-116,7.基金项目
新疆维吾尔自治区"天山英才医药卫生高层次人才培养计划中青年骨干人才"(TSYC202301B029) This work was supported by the Xinjiang Uygur Autonomous Region"Tianshan Elite Medical and Health High-level Talent Training Program Young Backbone Talents"(TSYC202301B029). （TSYC202301B029）
